Post a Free Blog

Submit A Press Release

Thursday, March 28, 2024
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Truck Series (TRUCK)
Ultimate Fighting Championship (UFC)
Uncategorized
US
Valorant
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
-- Advertisement --spot_img
HomeBusinessEarnings Release Is AbbVie Inc. A Buy?

Earnings Release Is AbbVie Inc. A Buy?

 AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2021 with double revenue.

“We are off to an excellent start to 2021, with strong performance across our core therapeutic areas and first quarter revenue and earnings results ahead of our expectations,” said  Richard A. Gonzalez, chairman and chief executive officer, AbbVie. “Our new products are delivering impressive performance and we are on the cusp of potential commercial approvals for more than a dozen new products or indications over the next two years — including five expected approvals in 2021.”

First-Quarter Results

  • Worldwide GAAP net revenues were  $13.010 billion, an increase of 51.0 percent on a reported basis. Worldwide adjusted net revenues of  $12.935 billion  increased 5.2 percent on a comparable operational basis.
  • Global net revenues from the immunology portfolio were  $5.744 billion, an increase of 12.9 percent on a reported basis, or 11.8 percent on an operational basis.
    • Global Humira net revenues of  $4.867 billion  increased 3.5 percent on a reported basis, or 2.6 percent on an operational basis. U.S. Humira net revenues were  $3.907 billion, an increase of 6.9 percent. Internationally, Humira net revenues were  $960 million, a decrease of 8.3 percent on a reported basis, or 12.6 percent on an operational basis, due to biosimilar competition.
    • Global Skyrizi net revenues were  $574 million.
    • Global Rinvoq net revenues were  $303 million.
  • Global net revenues from the hematologic oncology portfolio were  $1.673 billion, an increase of 8.0 percent on a reported basis, or 7.3 percent on an operational basis.
    • Global Imbruvica net revenues were  $1.268 billion, an increase of 2.9 percent, with U.S. net revenues of  $999 million  and international profit sharing of  $269 million.
    • Global Venclexta net revenues were  $405 million, an increase of 27.9 percent on a reported basis, or 24.5 percent on an operational basis.
  • Global net revenues from the aesthetics portfolio were  $1.141 billion, an increase of 34.9 percent on a comparable operational basis.
    • Global Botox Cosmetic net revenues were  $477 million, an increase of 44.7 percent on a comparable operational basis.
  • Global net revenues from the neuroscience portfolio were  $1.248 billion, an increase of over 100.0 percent on a reported basis, or 10.9 percent on a comparable operational basis.
    • Global Botox Therapeutic net revenues were  $532 million, an increase of 7.0 percent on a comparable operational basis.
    • Global Vraylar net revenues were  $346 million, an increase of 21.2 percent on a comparable operational basis.
    • Global Ubrelvy net revenues were  $81 million.
  • On a GAAP basis, the gross margin ratio in the first quarter was 67.6 percent. The adjusted gross margin ratio was 83.9 percent.
  • On a GAAP basis, selling, general and administrative expense was 21.8 percent of net revenues. The adjusted SG&A expense was 21.2 percent of net revenues.
  • On a GAAP basis, research and development expense was 13.7 percent of net revenues. The adjusted R&D expense was 11.6 percent of net revenues, reflecting funding actions supporting all stages of our pipeline.
  • On a GAAP basis, the operating margin in the first quarter was 31.5 percent. The adjusted operating margin was 51.0 percent.
  • On a GAAP basis, net interest expense was  $622 million.
  • On a GAAP basis, the tax rate in the quarter was 8.1 percent. The adjusted tax rate was 12.3 percent.
  • Diluted EPS in the first quarter was  $1.99  on a GAAP basis. Adjusted diluted EPS, excluding specified items, was  $2.95.

– Reports First-Quarter Diluted EPS of $1.99 on a GAAP Basis; Adjusted Diluted EPS of $2.95
– Delivers First-Quarter Net Revenues of $13.010 Billion on a GAAP Basis, an Increase of 51.0 Percent on a Reported Basis; Adjusted Net Revenues Were $12.935 Billion
– First-Quarter Global Net Revenues from the Immunology Portfolio Were $5.744 Billion, an Increase of 12.9 Percent on a Reported Basis, or 11.8 Percent on an Operational Basis; U.S. Humira Net Revenues Were $3.907 Billion, an Increase of 6.9 Percent; Internationally, Humira Net Revenues Were $960 Million, a Decrease of 8.3 Percent on a Reported Basis, or 12.6 Percent on an Operational Basis, Due to Biosimilar Competition; Global Skyrizi Net Revenues Were $574 Million; Global Rinvoq Net Revenues Were $303 Million
– First-Quarter Global Net Revenues from the Hematologic Oncology Portfolio Were $1.673 Billion, an Increase of 8.0 Percent on a Reported Basis, or 7.3 Percent on an Operational Basis; Global Imbruvica Net Revenues Were $1.268 Billion, an Increase of 2.9 Percent, with U.S. Net Revenues of $999 Million and International Profit Sharing of $269 Million; Global Venclexta Net Revenues Were $405 Million
– First-Quarter Global Net Revenues from the Aesthetics Portfolio Were $1.141 Billion; Global Botox Cosmetic Net Revenues Were $477 Million
– First-Quarter Global Net Revenues from the Neuroscience Portfolio Were $1.248 Billion; Global Botox Therapeutic Net Revenues Were $532 Million; Global Vraylar Net Revenues Were $346 Million
– Raises 2021 GAAP Diluted EPS Guidance Range from $6.69 to $6.89 to $7.27 to $7.47; Raises 2021 Adjusted Diluted EPS Guidance Range from $12.32 to $12.52 to $12.37 to $12.57

CWEB Analyst’s have initiated a BUY Rating for   AbbVie (NYSE:ABBV)   and potential upside of $190 in 2021. We believe that total revenue will grow faster than expenses in 2021. Revenue has doubled in some sectors of the company which is a very positive sign. We expect another jump in revenue in the second quarter of 2021.

Subscribe to get Latest News Updates

Latest News Articles

You may like more
more

Robinhood Gains 3 percent on Credit Card Launch Plans

Robinhood Markets (NASDAQ:HOOD) stock rose more than 3% intra-day...

Bloom Energy’s Price Target Cut at Susquehanna

Susquehanna analysts adjusted their price target for Bloom Energy...

Nio Shares Drops 6 percent Following Slashed Q1 Delivery Outlook

NIO (NYSE:NIO) shares fell more than 6% intra-day today...

nCino Shares Jump 19 percent Following Q4 Earnings

nCino (NASDAQ:NCNO) shares surged more than 19% intra-day today...